Harrow Inc (HROW)

May 28, 2025, 3:20 PM EDT - 5 days ago

Harrow: Epic Growth & Operating Leverage On Full Display

May 14, 2025, 7:00 AM EDT - 19 days ago

Harrow to Present at Two Investor Conferences in May

May 10, 2025, 6:17 PM EDT - 23 days ago

Harrow, Inc. (HROW) Q1 2025 Earnings Call Transcript

May 8, 2025, 4:01 PM EDT - 25 days ago

Harrow Announces First-Quarter 2025 Financial Results

May 5, 2025, 7:00 AM EDT - 4 weeks ago

Harrow to Report First Quarter 2025 Financial Results After Market Close on May 8, 2025

Apr 24, 2025, 10:00 AM EDT - 5 weeks ago

NORDIC GROUP B.V. THROUGH ITS SUBSIDIARY NORDIC PHARMA, INC.

Apr 10, 2025, 7:00 AM EDT - 7 weeks ago

Harrow Expands VEVYE® Access for All Program to ImprimisRx's Klarity-C Patients

Mar 29, 2025, 4:30 PM EDT - 2 months ago

Harrow: When Cheaper Doesn't Mean Attractive (Rating Upgrade)

Mar 28, 2025, 2:00 PM EDT - 2 months ago

Harrow, Inc. (HROW) Q4 2024 Earnings Conference Call

Mar 28, 2025, 1:39 PM EDT - 2 months ago

Harrow Inc.: Roll The Dice For Strong Upside Prospects As Earnings Ramp

Mar 27, 2025, 4:01 PM EDT - 2 months ago

Harrow Announces Fourth-Quarter and Year-End 2024 Audited Financial Results

Mar 27, 2025, 10:45 AM EDT - 2 months ago

Harrow To Report Fourth Quarter and Audited Year-End 2024 Financial Results After Market Close on March 27, 2025

Mar 24, 2025, 7:00 AM EDT - 2 months ago

Harrow Announces Transitional Pass-Through Reimbursement Status for TRIESENCE® (Triamcinolone Acetonide Injectable Suspension) 40 mg/mL

Mar 17, 2025, 4:01 PM EDT - 2 months ago

Harrow Provides Fourth Quarter and Year-End 2024 Unaudited Preliminary Financial Results and 2025 Revenue Guidance

Mar 17, 2025, 7:00 AM EDT - 2 months ago

Harrow Launches VEVYE® Access for All

Mar 11, 2025, 7:00 AM EDT - 2 months ago

Harrow Executes Five-Year Strategic Supply and Development Agreement for TRIESENCE®

Mar 3, 2025, 7:15 AM EST - 3 months ago

Harrow to Report Fourth Quarter and Year-End 2024 Financial Results After Market Close on March 17, 2025

Mar 1, 2025, 8:50 AM EST - 3 months ago

Smallcap Eyecare Pharma Company Harrow Health Has Two Major Catalysts For 2025

Feb 17, 2025, 7:35 AM EST - 3 months ago

I Am Loading Up Big Dividends For My Golden Years

HQH

Jan 27, 2025, 7:30 AM EST - 4 months ago

Harrow Partners with Cencora to Launch “Harrow Cares” Program, Making IHEEZO® and TRIESENCE® More Accessible and Affordable for Retina Specialists and Their Patients

COR

Jan 7, 2025, 7:00 AM EST - 5 months ago

Harrow Appoints Amir H. Shojaei as Chief Scientific Officer

Jan 3, 2025, 3:43 PM EST - 5 months ago

Those Derisked Baby Bonds Of Harrow, Inc.

Dec 14, 2024, 12:09 AM EST - 6 months ago

Harrow: The Triesence Relaunch

Nov 21, 2024, 7:00 AM EST - 6 months ago

Harrow's ImprimisRx Subsidiary Receives $34.9 Million Unanimous Jury Verdict Award in ImprimisRx, LLC v. OSRX, Inc.

Nov 15, 2024, 7:00 AM EST - 7 months ago

Harrow Announces Participation in Upcoming Investor Conferences

Nov 14, 2024, 2:56 PM EST - 7 months ago

Harrow, Inc. (HROW) Q3 2024 Earnings Call Transcript

Nov 13, 2024, 4:34 PM EST - 7 months ago

Harrow Announces Third Quarter 2024 Financial Results

Nov 13, 2024, 7:00 AM EST - 7 months ago

Harrow Launches Access and Affordability Program with Price Reductions for Branded Products

GDRX

Nov 12, 2024, 7:00 AM EST - 7 months ago

Harrow Announces Market Access Wins for VEVYE®

Nov 11, 2024, 6:37 AM EST - 7 months ago

Harrow: VEVYE And Its Impact On The DED Market

Nov 7, 2024, 7:00 AM EST - 7 months ago

Harrow Partners with Asembia to Enhance Provider and Patient Experience Through Nationwide Digital Services and Hub Support for Harrow's Branded Eyecare Products

Oct 31, 2024, 7:00 AM EDT - 7 months ago

Harrow To Report Third Quarter 2024 Financial Results After Market Close on November 13, 2024

Oct 12, 2024, 10:30 AM EDT - 8 months ago

I Am Banking On The Silver Tsunami With Big Dividends

THQ XOMA

Oct 3, 2024, 7:00 AM EDT - 8 months ago

Harrow Relaunches TRIESENCE®

Oct 2, 2024, 12:10 PM EDT - 8 months ago

Harrow Inc (HROW) Shares Up 3.26% on Oct 2

Sep 25, 2024, 12:02 PM EDT - 8 months ago

Harrow Announces Nashville Expansion

Sep 3, 2024, 7:00 AM EDT - 9 months ago

Harrow to Present at Three Investor Conferences in September in New York

Aug 16, 2024, 3:42 PM EDT - 10 months ago

Harrow: Bulls On Parade

Aug 7, 2024, 4:01 PM EDT - 10 months ago

Harrow Announces Second Quarter 2024 Financial Results

Aug 1, 2024, 3:29 AM EDT - 10 months ago

Don't Buy AI Stocks, Buy The Best Dividend Total Return Stocks

ARLP BEPC BMY BTI BXSL DOW EG

Jul 25, 2024, 7:00 AM EDT - 11 months ago

Harrow To Report Second Quarter 2024 Financial Results After Market Close on August 7, 2024

Jul 12, 2024, 7:00 AM EDT - 11 months ago

Harrow to Attend 2024 ASRS Annual Meeting

Jul 9, 2024, 7:00 AM EDT - 11 months ago

Harrow Enters into 340B Prime Vendor Program Contract with Apexus™ for IHEEZO® and Other Key Harrow Products

Jul 3, 2024, 9:41 AM EDT - 11 months ago

Top 3 Health Care Stocks That May Crash This Quarter

LBPH LLY

Jun 24, 2024, 11:42 AM EDT - 1 year ago

Harrow Successfully Manufactures Triesence; Management Credibility Soars

Jun 20, 2024, 7:00 AM EDT - 1 year ago

Harrow Provides TRIESENCE® Relaunch Update

Jun 6, 2024, 8:00 AM EDT - 1 year ago

Melt Pharmaceuticals Announces First Patient Dosed in Pivotal Phase 3 Program of Its Lead Product Candidate, MELT-300, for Needle- and Opioid-Free Sedation in Patients Undergoing Cataract Surgery

Jun 5, 2024, 1:00 PM EDT - 1 year ago

The 'Undercovered' Dozen From May 2024

ACI AGCO BDN DE FDX HUMA PPLT

Jun 5, 2024, 7:00 AM EDT - 1 year ago

Harrow Announces 52-Week Data from VEVYE® ESSENCE-2 Open-Label Extension Study

May 14, 2024, 10:48 AM EDT - 1 year ago

Harrow, Inc. (HROW) Q1 2024 Earnings Call Transcript